[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"proteinuria\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:proteinuria":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,44,70,94,126,156,183,215,240,268,297,361,383,411,432,462,502,523],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100474390","phase-3-a-study-to-learn-more-about-how-safe-the-study-treatment-finerenone-is-in-long-term-use-when-taken-with-an-ace-inhibitor-or-angiotensin-receptor-blocker-over-18-months-of-use-in-children-and-young-adults-from-1-to-18-years-of-age-with-chronic-kidney-disease-and-proteinuria-100474390",false,"NCT05457283","A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria","An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria","FIONA OLE","Inclusion Criteria:\n\n* Participants must be ≥1 year to 18 years of age, at the time of signing the informed consent\u002Fassent.\n* Prior participation in the finerenone Phase 3 study FIONA (19920) and not permanently discontinued from treatment by the end of treatment (EoT) visit in FIONA.\n* Participants must have a clinical diagnosis of chronic kidney disease (CKD) at Visit 1 which is defined as\n\n  * CKD stages 1-3 (estimated glomerular filtration rate \\[eGFR\\] ≥30 mL\u002Fmin\u002F1.73m\\^2) for children ≥1 year to \\\u003C19 years of age at FIONA EoT and at Visit 1\n* Treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at optimized doses defined as maximally tolerable doses within the recommended dose range according to guidelines on blood pressure (BP) management, unchanged for at least 30 days prior to Visit 1.\n* K+ ≤5.0 mmol\u002FL for children ≥2 years of age at both FIONA EoT and Visit 1, and ≤5.3 mmol\u002FL for children \\\u003C2 years of age at both FIONA EoT and Visit 1\n* Participants who have reached legal age of consent: Capable of giving signed informed consent.\n* Participant is able to receive enteral feeding (solid food, bottle or cup fed, feeding through nasogastric or gastric feeding tubes) with or without breastfeeding.\n\nExclusion Criteria:\n\n* Planned urological surgery expected to influence renal function\n* Patients who are candidates for renal transplantation, i.e., a kidney transplantation scheduled within the study time frame\n* Systemic hypertension Stage 2 defined according to institutional guidelines on BP management at Visit 1.\n* Systemic hypotension defined as symptomatic hypotension or a mean systolic BP below the 5th percentile for age, sex and height but no lower than 80 mmHg for participants \\\u003C18 years and symptomatic hypotension or a mean systolic blood pressure (SBP) \\\u003C90 mmHg in participants ≥18 years at Visit 1.\n* Known hypersensitivity to the study treatment (active substance or excipients)\n* Severe hepatic insufficiency defined by e.g. Child-Pugh C or analogous scores.\n* Participants using rituximab, cyclophosphamide, abatacept, or intravenous glucocorticoids\n* Concomitant therapy with a mineralocorticoid receptor antagonist (MRA)(eplerenone, spironolactone, esaxerenone, canrenone), any renin inhibitor (aliskiren, enalkiren, remikiren), any sodium-glucose co-transporter-2 (SGLT2) inhibitor (SGLT2i), sacubitril\u002Fvalsartan combination (ARNI), or potassium-sparing diuretic (amiloride, triamterene)\n* Concomitant therapy with both ACEI and ARBs together\n* Concomitant therapy with strong cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors, moderate or strong CYP3A4 inducers\n* Previous assignment to treatment during this study\n* Simultaneous participation in another interventional clinical study (e.g., Phase 1 to 4 clinical studies).\n* Any suspected (serious) adverse event related to study intervention which led to permanent discontinuation during the FIONA study.\n* Pregnant or breastfeeding or intention to become pregnant during the study","ALL","1 Year","18 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine.\n\nThe kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known as hypertension. Vice versa, hypertension and proteinuria can also contribute to worsening of CKD. Therefore, the treatment of CKD aims to control blood pressure and proteinuria. There are treatments available for doctors to prescribe to children with CKD and hypertension and\u002For proteinuria. These include \"angiotensin-converting enzyme inhibitors\" (ACEI) and \"angiotensin receptor blockers\" (ARB). Both ACEI and ARB can help improve kidney function by reducing the activity of the renin-angiotensin-aldosterone system (RAAS). The RAAS is a system that works with the kidneys to control blood pressure and the balance of fluid and electrolytes in the blood. In people with CKD, the RAAS is often too active, which can impair the ability of the kidneys to work properly and cause hypertension and proteinuria. However, ACEI or ARB treatment alone does not work for all patients with CKD as they only target the angiotensin part of the renin-angiotensin-aldosterone system.\n\nThe study treatment, finerenone, is expected to help control RAAS overactivation together with an ACEI or ARB.\n\nSo, the researchers in this study want to learn more about whether finerenone given in addition to either an ACEI or ARB can help their kidney function.\n\nThe main purpose of this study is to learn how safe the treatment is when used of finerenone in addition to an ACEI or ARB in long-term.\n\nTo see how safe the treatment is, the study team will collect information on medical problems which are also known as \"treatment emergent adverse events\" (TEAEs). And they will also collect levels of an electrolyte called potassium in the blood by taking blood samples, and measure blood pressure during the study.\n\nThe secondary purpose of this study is to learn how well long-term use of finerenone can reduce the amount of protein in the participants' urine and benefit kidney function when taken with standard of care.\n\nTo see how the treatment works, the study team will collect participants' urine samples to assess urinary albumin-to-creatinine ratio (UACR) and urinary protein-to-creatinine ratio (UPCR), which are important assessments for calculating the level of protein in the urine. Researchers will also collect blood samples to analyze serum creatinine and calculate estimated glomerular filtration rate (eGFR). A significant decline in eGFR indicates worsening kidney function.\n\nThe study will include participants who had previously participated in FIONA study (NCT05196035). The participants will be aged from 1 year up to 18 years.\n\nThe participants will be in the study for approximately 19 months. They will take study treatment for up to 18 months and will be follow up for 1 month. During this period, at least 12 visits are planned for patients who newly start finerenone, and at least 8 visits for patients who already received finerenone.\n\nIn the visit, the study team will:\n\n* have their blood pressure, heart rate, temperature, height and weight measured\n* have blood and urine samples taken\n* have physical examinations\n* have their heart examined by an electrocardiogram and echocardiography (a sonogram of the heart)\n* answer questions about their medication and whether they have any adverse events, or have their parents or guardian's answer\n* answer questions about how they are feeling, or have their parents or guardian's answer\n* answer question about how they like the study medication, or have their parents or guardian's answer The doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.\n\nThe doctors will check the participants' health about 30 days after the participants take their last treatment.",[28,29,30],"Chronic Kidney Disease","Proteinuria","Children","RECRUITING","2026-06-25",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":35},"2022-11-08",{"date":39,"type":22},"2028-12-28",{"name":41,"class":42},"Bayer","INDUSTRY",179,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100271830","improving-renal-complications-in-adolescents-with-type-2-diabetes-through-research-cohort-study-national-icare-study-100271830","NCT02818192","Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)","iCARE","Inclusion Criteria:\n\n* All youth with T2D that do not meet exclusion criteria are eligible for the study.\n\nCriteria for Diagnosis of T2D:\n\n1. Diagnosis of diabetes will be made according to the Canadian Diabetes Association criteria. There must be 2 abnormal blood glucose tests on different days OR 1 abnormal blood glucose test + symptoms of diabetes:\n\n   * Fasting plasma glucose of \\> 7.0 mmol\u002FL or\n   * Random glucose \\> 11.1mmol\u002FL or\n   * 2 hour glucose \\> 11.1 mmol\u002FL after a standard oral glucose tolerance test (75g) or\n   * Hemoglobin A1c value ≥ 6.5%\n2. Distinguishing T2D from type 1 diabetes (T1D) will be based on clinical risk factors including:\n\n   * Presence of overweight\u002Fobesity,\n   * Other evidence of insulin resistance (acanthosis nigricans)\n   * Family history of type 2 diabetes (1st degree relative)\n   * Intrauterine exposure to hyperglycemia,\n   * Family heritage from a high-risk ethnic group (Indigenous, Hispanic, South Asian, Asian or African descent)\n   * Absence of diabetes associated auto-antibodies\n   * HNF-1 alpha heterozygote or homozygote\n\nExclusion Criteria:\n\n1. Diabetes secondary to medication use or surgery\n2. Antibodies suggestive of type 1 diabetes\n3. Current treatment with oral steroids or immunosuppressive agents as they may interfere with cortisol assessment and inflammatory markers\n4. Ever cancer\n5. Other chronic illness associated with systemic inflammation (ex. Juvenile rheumatoid arthritis, Crohns disease)\n6. Patient and or caregiver unable or unwilling to provide voluntary informed assent\u002Fconsent","10 Years",{"count":53,"type":22},500,"OBSERVATIONAL","The overall aim of the project is to elucidate the primary bio-psycho-social (BPS) risk factors for albuminuria in youth with type 2 diabetes (T2D) and the mechanisms by which they cause renal injury. The Study aims include:\n\n1. Characterize the primary BPS risk factors associated with prevalent and progressive albuminuria in youth with T2D.\n2. Determine individual, family and community level factors that influence biological and psychological risk factors and behaviors (adherence) that could be modified to protect against prevalent and progressive albuminuria.\n3. Determine if systemic and renal inflammation is the common pathway through which BPS risk factors lead to albuminuria in youth with T2D.\n\nStudy Hypotheses include:\n\n1. Biological factors (poor glycemic control and systolic ambulatory hypertension), and psychological and social adversity (stress, mental distress and poverty) are significant predictors of prevalent and progressive albuminuria in youth with T2D.\n2. Community and family support will be negatively associated with stress, and a lower risk of both prevalent and progressive albuminuria.\n3. Systemic and renal inflammation is the common pathway through which BPS risk factors lead to albuminuria in youth with T2D.",[57,29,58,59],"Type 2 Diabetes","Stress","Nephropathy",{"date":61,"type":35},"2026-06-29",{"date":63,"type":35},"2017-01",{"date":65,"type":22},"2027-03",{"name":67,"class":68},"University of Manitoba","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100454322","phase-3-a-study-to-learn-more-about-how-well-the-study-treatment-finerenone-works-how-safe-it-is-how-it-moves-into-through-and-out-of-the-body-and-the-effects-it-has-on-the-body-when-taken-with-an-ace-inhibitor-or-angiotensin-receptor-blocker-in-children-with-chronic-kidney-disease-and-proteinuria-100454322","NCT05196035","A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria","A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK\u002FPD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to \u003C18 Years of Age, With Chronic Kidney Disease and Proteinuria","FIONA","Inclusion Criteria:\n\n* Participants must be 6 months to \\\u003C18 years old at the time when the informed consent\u002Fassent is signed\n* Participants must have a clinical diagnosis of chronic kidney disease (CKD) at screening which is defined as\n\n  * CKD stages 1-3 (eGFR ≥30 mL\u002Fmin\u002F1.73m\\^2) for children ≥1 year to \\\u003C18 years of age or\n  * a serum creatinine ≤ 0.40 mg\u002FdL for infants 6 months to \\\u003C 1 year of age and\n  * severely increased proteinuria as defined by\n\n    * Urinary protein-to-creatinine ratio (UPCR) of ≥ 0.50 g\u002Fg in participants ≥ 2 years with CKD stage 2 and 3 or\n    * UPCR ≥ 1.0 g\u002Fg for patients \\\u003C 2 years of age or ≥ 2 years of age and with CKD stage 1\n* Participants must have stable kidney function between screening and D0 defined as:\n\n  * For participants with a creatinine of \\> 0.8 mg\u002FdL at screening: no increase or decrease in eGFR by ≥ 20% at D0\n  * For participants with a creatinine of ≤ 0.8 mg\u002FdL at screening: no increase or decrease in creatinine ≥ 0.15 mg\u002FdL at D0.\n* Treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at optimized doses defined as maximally tolerable doses within the recommended dose range according to guidelines on blood pressure management, unchanged for at least 30 days prior to screening\n* K+ ≤5.0 mmol\u002FL for children ≥2 years of age at both screening and D0, and ≤5.3 mmol\u002FL for children \\\u003C2 years of age at both screening and D0\n\nExclusion Criteria:\n\n* Planned urological surgery expected to influence renal function\n* Children with hemolytic uremic syndrome (HUS) diagnosed ≤6 months prior to screening\n* Patients with nephrotic syndrome receiving albumin infusions within the last 6 months prior to screening\n* Patients who are candidates for renal transplantation, i.e., a kidney transplantation scheduled within the study time frame\n* Renal allograft in place\n* Bilateral renal artery stenosis\n* Acute kidney injury requiring dialysis within 6 months prior to screening\n* Systemic hypertension stage 2 in children ≥1 year of age defined according to guidelines on blood pressure management at screening or randomization\n* Systolic blood pressure (SBP) above 110 mmHg in infants 6 months to \\\u003C1 year of age at screening or randomization\n* Systemic hypotension defined as a systolic blood pressure below the 5th percentile for age, sex and height at either screening or randomization but no lower than 80 mmHg (although for some participants the 5th percentile of SBP is \\\u003C 80 mmHg they must be excluded if their SBP is \\\u003C80 mmHg)\n* Participants with immune-mediated CKD using rituximab, cyclophosphamide, abatacept, or high-dose glucocorticoids, within \\\u003C6 months prior to screening","6 Months","17 Years",{"count":81,"type":22},219,[25],"Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine.\n\nThe kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known as hypertension. Vice versa, hypertension and proteinuria can also contribute to worsening of CKD. Therefore, the treatment of CKD aims to control blood pressure and proteinuria. There are treatments available for doctors to prescribe to children with CKD and hypertension and\u002For proteinuria. These include \"angiotensin-converting enzyme inhibitors\" (ACEI) and \"angiotensin receptor blockers\" (ARB). Both ACEI and ARB can improve kidney function by helping the renin-angiotensin-aldosterone system (RAAS) to work normally. The RAAS is a system that works with the kidneys to control blood pressure and the balance of fluid and electrolytes in the blood. In people with CKD, the RAAS is often too active, which can stop the kidneys from working properly and cause hypertension and proteinuria. However, ACEI or ARB treatment alone does not work for all patients with CKD as they only target the angiotensin part of the renin-angiotensin-aldosterone system.\n\nThe study treatment, finerenone, is expected to help control RAAS overactivation together with an ACEI or ARB.\n\nSo, the researchers in this study want to learn more about whether finerenone given in addition to either an ACEI or ARB can help their kidney function.\n\nThe main purpose of this study is to learn more about whether finerenone added to either ACEI or ARB can help reduce the amount of protein in the participants' urine more than a placebo. A placebo looks like a treatment but does not have any medicine in it. Participants will also continue to receive their other medications.\n\nTo see how the treatment work, the doctors will take samples of the participants' urine to measure their protein levels before and during taking treatment and after their last treatment. In addition, blood samples will be taken to monitor kidney function, electrolytes and the amount of finerenone in the blood as well as for other tests.\n\nThis study will include children with CKD and proteinuria aged from 6 months up to less than 18 years. The participants will take:\n\n* either finerenone or the placebo, in addition to\n* either ACEI or ARB, whichever they take as part of their normal treatment\n\nTwo visits are required up to 104 days, to check whether a child can take part in the treatment phase of the study. If participants qualify for the treatment phase, they will then undergo treatment for about 180 days. During this time, they will visit the study site at least 7 times. During these visits, the participants will:\n\n* have their blood pressure, heart rate, temperature, height and weight measured\n* have blood and urine samples taken\n* have physical examinations\n* have their heart examined by an electrocardiogram and echocardiography (a sonogram of the heart)\n* answer questions about their medication and whether they have any adverse events , or have their parents or guardians answer\n* answer questions about how they are feeling, or have their parents or guardians answer\n* answer question about how they like the study medication, or have their parents or guardians answer\n\nThe doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.\n\nThe doctors will check the participants' health about 30 days after the participants take their last treatment.",[28,29],"2026-06-18",{"date":87,"type":35},"2026-06-22",{"date":89,"type":35},"2022-03-28",{"date":91,"type":22},"2027-06-30",{"name":41,"class":42},164,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":105,"conditions":106,"keywords":111,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":125},"100131289","phase-2-rituximab-plus-cyclosporine-in-idiopathic-membranous-nephropathy-100131289","NCT00977977","Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study\n2. Male or female, \\>= 18 years of age\n3. Nephrotic range proteinuria that persists for at least 6 months post diagnosis of membranous nephropathy greater than 3.5 grams \u002F24 hours (based on 24-hour urine collection).\n\n   a. If the subject s renal function rapidly declines in less than 6 months could proceed with immunosuppression therapy sooner such as complications of the nephrotic syndrome that are not controlled with supportive therapy or evidence of decline in glomerular filtration rate or proteinuria \\>8 grams\u002Fday. Subjects with declining renal function and\u002For high-grade proteinuria due to MN are considered \"high risk\" subjects and have a higher probability of progression to end stage kidney disease.\n4. Nephrotic range proteinuria (\\>3.5 g\u002F24 hours) that persists despite angiotensin antagonist therapy (ACE inhibitor or ARB) for at least 2 months unless intolerant.\n\n   a. The rationale is that blockade of the renin angiotensin system (RAAS) is widely considered to be part of the standard of care treatment for subjects with the nephrotic syndrome. Nephrotic range proteinuria will be defined as an estimated average proteinuria \\>3.5 g\u002F24 hours in adults based on at least two 24-hour urine protein excretions obtained prior to initiating therapy. Incomplete urine\n\n   collections (based on inadequate creatinine excretion) will be excluded.\n5. Renal biopsy within the past 24 months must reveal typical changes of membranous nephropathy by light and electron microscopy or a positive anti-PLA2R antibody test in the serum. There has been a change in the management strategies for MN such that a renal biopsy is not absolutely required for diagnosis if patient has positive circulating anti-PLA2R antibody.\n\n   a. Based on published KDIGO 2021 Clinical Practice Guidelines 3.1.1 patients with MN who are positive for anti-PLA2R do not require renal biopsy as long as renal function is normal (eGFR \\>60) and has not had immunosuppression as it has been demonstrated that results of the biopsy have not altered clinical approach and management. If not PLA2R positive, renal biopsy within 24 months is still required.\n6. Blood pressure \\\u003C=140\u002F90 on \\>75% of measurement while on anti-hypertensive treatment for at least 1-2 months.\n7. There is no evidence to suggest secondary forms of membranous nephropathy.\n8. Ability to take oral medication and be willing to adhere to the cyclosporine regimen\n9. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for 12 months after the last Rituximab infusion.\n10. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.\n11. Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Estimated GFR\\\u003C40 ml\u002Fmin\u002F1.73 m\\^2 from the preceding 2 months prior to enrollment while on ACEI\u002FARB therapy.\n2. Immunosuppressive medications or experimental medications of any type during the three-month period prior to initiating Rituximab and cyclosporine.\n3. Prior exposure to cyclosporine or tacrolimus for more than 6 months and\u002For evidence of intolerance or toxicity associated with cyclosporine treatment of any duration including irreversible azotemia, liver dysfunction or hypertension\n4. Rituximab use within the previous 12 months.\n5. Clinically significant medical conditions (i.e., severe heart failure NYHA class IV, uncontrolled coronary artery disease\u002Funstable angina), which in the opinion of the investigator, could increase the subject s risk of participating in the study or could confound the interpretation of the results of the study.\n6. Positive HIV serology\n7. Positive HCV serology\n8. Active acute or chronic infection requiring antimicrobial therapy or serious viral infection cytomegalovirus, herpes simplex, varicella zoster virus (chicken pox or shingles), Parvovirus B19 (can be based on previous medical records within the past 24-months)\n9. Live viral vaccines within one month prior to Rituximab.\n10. Pregnancy or lactation\n11. Cancer diagnosis or cancer recurrence within the preceding 5 years, excluding basal cell carcinoma of the skin. The rationale is that immunosuppression may accelerate cancer progression.\n12. Clinical evidence of cirrhosis or chronic active liver disease sufficiently severe to impair cyclosporine metabolism; this would include a prolonged prothrombin time.\n13. Cytopenia (neutrophils \\\u003C1500\u002Fmm\\^3 and\u002For thrombocytopenia \\\u003C75,000) and\u002For CD4 T cell count \\\u003C200\u002Fmm\\^3). The rationale is that Rituximab therapy may be followed by cytopenia with the granulocyte lineage being at greatest risk. Patients with low CD4 T cell counts are prone to infection which can be exacerbated by Rituximab.\n14. Diabetes mellitus. The rationale is that diabetes may lead to worsening of proteinuria that would not respond to immunosuppression and would confound the results.","90 Years",{"count":102,"type":22},30,[104],"PHASE2","Background:\n\n* Membranous nephropathy is associated with damage to the walls of the glomeruli, the small blood vessels in the kidneys that filter waste products from the blood. This damage causes leakage of blood proteins into the urine and is associated with low blood protein levels, high blood cholesterol values, and swelling of the legs. These problems can decrease or go away without treatment in about 25 percent of patients, but if they persist, some patients may experience impaired (or loss of) kidney function, blood vessel and heart disease, and a risk of forming blood clots in veins.\n* Kidney biopsies that show that antibodies have been deposited along the glomeruli suggest that specialized cells of the immune system, called B and T cells, are causing damage to the kidneys through their increased activity. To suppress the action of B and T cells and to decrease the harmful deposits in the kidneys, drug treatments are required.\n* Patients with membranous nephropathy are often treated with immunosuppressive drugs such as cyclosporine or cytoxan plus steroids that attempt to reduce or suppress the activity of the immune system, decrease antibody production, and reduce antibody deposits in the kidney. However, not everyone responds to these medications and the kidney disease can return in some patients when the drugs are stopped. Also, there are side effects associated with long term usage of these medications. Rituximab, a different immunosuppressant, has also been used for this purpose. Although cyclosporine and Rituximab have been used separately, they have not been tried in combination as a possible treatment for membranous nephropathy.\n\nObjectives:\n\n\\- To determine the safety and effectiveness of combining rituximab and cyclosporine to treat membranous nephropathy.\n\nEligibility:\n\n\\- Individuals 18 years of age and older who have been diagnosed with membranous nephropathy based on a kidney biopsy done within the preceding 24 months, and who have had excess levels of protein in the urine for at least 6 months based on urine and blood tests.\n\nDesign:\n\n* Potential participants will be screened with an initial clinic evaluation and full medical history.\n* Before the treatment, there will be a run-in period that will last up to 2 months. During this time, participants will be placed on a blood pressure lowering medication and will not take any other immunosuppressant medications.\n* Participants will visit the NIH clinical center for a baseline evaluation, four intravenous infusions of rituximab, and also at 1- to 6-month intervals throughout the study.\n* Active treatment period will involve a 6-month course of cyclosporine and a total of four doses of rituximab. Participants will take cyclosporine tablets twice daily, and have two infusions of rituximab given 2 weeks apart, After 6 months, the cyclosporine dose will slowly be decreased over several weeks and then completely discontinued. Participants will then receive another course (two doses 2 weeks apart) of rituximab, depending on results of blood work.\n* Participants will have frequent blood and urine tests performed to monitor the results of treatment and reduce the chance of side effects.",[107,29,108,109,110],"Nephrotic Syndrome","Autoimmune Disease","Glomerular Disease","Membranous Glomerulonephritis",[112,107,113,114,29],"Kidney Disease","Autoimmune Diseases","Clinical Trial","2026-06-11",{"date":117,"type":35},"2026-06-12",{"date":119,"type":35},"2010-12-22",{"date":121,"type":22},"2027-12-31",{"name":123,"class":124},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",2,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":69},"100610222","phase-1-sparsentan-for-the-treatment-of-vegf-signaling-pathway-inhibitor-associated-proteinuria-100610222","NCT07224776","Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria","Inclusion Criteria:\n\n1. Adults (≥ 18 years old) with active malignancy who are currently treated with VSPIs\n2. New high-grade proteinuria, defined as ≥ 2+ proteinuria on dipstick or a calculated urinary protein-to-creatinine ratio ≥ 1.0 g\u002Fg\n3. Able to provide written inform consent\n\nExclusion Criteria:\n\n1. Estimated glomerular filtration rate (eGFR) \\\u003C 45 ml\u002Fmin\u002F1.73m2\n2. Baseline high grade proteinuria ≥ 2+ proteinuria on dipstick or a calculated urinary protein-to creatinine ratio or microalbumin-to-creatinine ≥ 1.0 g\u002Fg prior to VSPI initiation\n3. Acute kidney injury defined as serum creatinine at least 1.5 times above the most proximal serum creatinine prior to VSPIs initiation\n4. History of allergic reactions or angioedema to any angiotensin receptor blocker (ARB) or ERA, including sparsentan or irbesartan, or has a hypersensitivity to any of the excipients in the study medications.\n5. Any potassium value \\>5 mEq\u002FL in the 14 days preceding high-grade proteinuria\n6. History of organ transplantation, with the exception of corneal transplants.\n7. History of congestive heart failure (New York Heart Association Class II-IV)\n8. History of clinically significant cerebrovascular disease (transient ischemic attack or stroke) and\u002For coronary artery disease (hospitalization for myocardial infarction or unstable angina, new onset of angina with positive functional tests, coronary angiogram revealing stenosis, or a coronary revascularization procedure) within 6 months prior to screening.\n9. Jaundice, hepatitis, or known hepatobiliary disease (excluding asymptomatic cholelithiasis), or alanine aminotransferase and\u002For aspartate aminotransferase \\>2 times the upper limit of the normal at screening.\n10. Body weight \\\u003C50 kg at screening\n11. Unable to hold renin-angiotensin-aldosterone system (RAAS) inhibitors such as angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), spironolactone, eplerenone, aliskiren, aldosterone blockers during run-in period\n12. Concomitant use of the following medications:\n\n    1. Inhibitors of endothelin system such as ambrisentan, bosentan, macitentan\n    2. Potassium-sparing diuretics such as amiloride, triamterene\n    3. Antiarrhythmic medications such as amiodarone, digoxin\n    4. Weight loss medications such as orlistat or amphetamine derivative agents\n    5. St. John's wort or other hypericum-derived products\n    6. Strong CYP3A inhibitors such as ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, telithromycin, ritonavir- or cobicistat-boosted regimens, boceprevir, telaprevir, conivaptan, mibefradil\n13. Pregnant or breastfeeding\n14. Concurrent participation in a study with an alternative experimental therapy that may interact with sparsentan\n15. Any condition that, in the view of the principal investigator, might place the patient at increased risk or compromise the integrity of the study\n16. Conflict with other study",{"count":133,"type":22},20,[135],"PHASE1","Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer who receive vascular endothelial growth factor inhibitors",[138,139,29,140],"Proteinuric Renal Disease","Proteinuric Kidney Disease","Proteinuria in Nephrotic Range",[142,143,144,145],"vascular endothelial growth factor inhibitors","cancer","proteinuria","endothelin-1 antagonist","NOT_YET_RECRUITING","2026-05-14",{"date":149,"type":35},"2026-05-18",{"date":151,"type":22},"2026-06-10",{"date":153,"type":22},"2028-12-01",{"name":155,"class":68},"Brigham and Women's Hospital",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":167,"conditions":168,"keywords":172,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":69},"100626153","optimizing-referral-pathways-for-patients-with-hematuria-and-moderate-severe-proteinuria-100626153","NCT07431931","Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria","Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria - Phase 2: A Quality Improvement Project","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Patients receiving care from any Geisinger primary care provider (record of an encounter with a Geisinger PCP within the last 2 years from date of survey implementation)\n* Patients with high-risk glomerulonephritis features i.e. positive test results for hematuria (urine dipstick result with blood 1+ or greater) and proteinuria (2+ or 3+ protein on dipstick or ACR≥300 mg\u002Fg or PCR ≥500 mg\u002Fg) collected within 12 months of index date.\n\nExclusion Criteria:\n\n* Patients with a nephrologist appointment in the last 12 months before the index date\n* Patients with a prior appointment with a nephrologist within the last 2 years before the positive urinalysis test for hematuria (1+ or greater)\n* Patients with a history of glomerulonephritis and\u002For kidney failure (dialysis or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m2, or kidney transplantation) at any time during the baseline\n* Patients receiving palliative care at any time during the baseline",{"count":164,"type":22},1200,[166],"NA","The purpose of the study is to evaluate prospectively the impact of an electronic health record (EHR) alert on primary care providers' (PCP) referral to Nephrology of Geisinger patients with high risk signs (blood and protein in the urine) of glomerulonephritis. This will help quantify the relative effectiveness of EHR alerts on PCPs' referral patterns.",[169,170,171,29,112],"Referral and Consultation","Glomerulonephritis","Hematuria",[173],"Hematuria; Proteinuria; Albuminuria; Glomerulonephritis; Clinical Decision Support; EHR Alert; Referral; Nephrology","2026-05-07",{"date":176,"type":35},"2026-05-12",{"date":178,"type":22},"2026-11",{"date":180,"type":22},"2027-12",{"name":182,"class":68},"Geisinger Clinic",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":195,"conditions":196,"keywords":202,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":125},"100636151","a-smart-phone-application-to-improve-adoption-of-the-2024-kidney-disease-improving-global-outcomes-kdigo-chronic-kidney-disease-ckd-guidelines-100636151","NCT07561957","A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines","A Smart Phone Application to Improve Adoption of the 2024 KDIGO CKD Guidelines","Inclusion Criteria:\n\n* Adults aged ≥16 years.\n* Diagnosed with CKD stages 1-5.\n* Owns a smartphone and is capable of using mobile applications.\n* Provides informed consent.\n\nExclusion Criteria:\n\n* Inability to provide informed consent due to a neurocognitive impairment.\n* Age 30 years or older\n\nThe study will be conducted in the already established SJH Young Adult Clinic, with anticipated expansion coinciding with the co-location Children's Health Ireland (CHI) on site.","16 Years","30 Years",{"count":193,"type":22},80,[166],"The goal of this study is to establish whether use of a digital intervention can improve adherence and alignment with the Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) 2024 Guidelines.\n\nA subset of the study will focus on whether the intervention improves outcomes for young adults living with CKD, in the context of the imminent co-location of Children's Health Ireland on the St. James's Hospital campus.\n\nYoung adults with CKD transitioning to adult services are recognised as a high-risk and vulnerable cohort, with many individuals unaware of increased cardiovascular risk and mortality¹². In response, and in the context of the co-location of Children's Health Ireland on the St. James's Hospital site, a young adult nephrology clinic has been established.\n\nThe KDIGO CKD 2024 Guidelines identify transition as a period of increased risk and include recommendations regarding cardiovascular risk factor targets and the use of therapies known to delay CKD progression³.\n\nElectronic communication is a preferred method for accessing health information among many young adults⁴⁵ and aligns with Sláintecare digital health strategies⁶. A recently established, award-winning St. James's Hospital renal smartphone application is currently used by over 3,000 individuals living with CKD.\n\nThe study aims to determine whether use of the application improves adherence to KDIGO guideline recommendations, with the objective of delaying CKD progression and associated complications. The application will support optimisation of care by signposting opportunities for evidence-based interventions (e.g., SGLT2 inhibitors, renin-angiotensin system inhibition) to healthcare providers. The application will also provide participants with tailored recommendations, reminders, educational materials, and collection of patient-reported outcome measures.\n\nDue to the diverse population and range of specialties at St. James's Hospital, the young adult clinic serves distinct subgroups, including individuals with sickle cell anaemia and survivors of cancer and haematological malignancies. These populations will be examined in the context of KDIGO guideline implementation, contributing to a limited international evidence base.\n\nThis research evaluates an intervention designed to improve care for adults living with chronic kidney disease.",[28,29,197,198,107,199,200,201],"Blood Pressure Control","Congenital Anomalies of the Kidneys and Urinary Tract","Sickle-Cell Nephropathy","Tuberous Sclerosis Complex","Cancer Survivors",[203,112,204,205],"Digital Interventions","Paediatric Nephrology","Transitional Nephrology","2026-04-24",{"date":208,"type":35},"2026-05-01",{"date":210,"type":35},"2026-01-14",{"date":212,"type":22},"2027-06-01",{"name":214,"class":68},"St. James's Hospital, Ireland",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":125},"100620507","phase-4-clinical-study-on-the-use-of-huaier-granules-for-the-treatment-of-proteinuria-related-to-bevacizumab-and-anlotinib-in-lung-cancer-patients-100620507","NCT07358520","Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients","Prospective, Multicenter, Parallel-Controlled Clinical Study on the Use of Huaier Granules for the Treatment of Bevacizumab- and Anlotinib-Related Proteinuria in Lung Cancer Patients","Inclusion Criteria:\n\n* Age ≥18 years;\n* Histopathologically confirmed diagnosis of lung cancer;\n* Receiving Bevacizumab or Anlotinib treatment;\n* Positive urine protein detection, with 0.15g \\\u003C 24-hour urinary protein quantification \\\u003C 3.5g;\n* No treatment with Huaier Granules within one month prior to enrollment;\n* Expected survival time not less than 6 months;\n* Voluntary participation in this study and provision of signed informed consent.\n\nExclusion Criteria:\n\n* Known allergy, contraindication, or caution to any component of Huaier Granules;\n* Inability to take oral medication;\n* Required or ongoing use of drugs known to potentially affect proteinuria, including but not limited to ACE inhibitors, glucocorticoids (\\>3 weeks), and Chinese patent medicines (as per respective drug prescribing information);\n* Proteinuria caused by underlying diseases, including but not limited to nephropathy, hypertension, urinary tract infection, systemic lupus erythematosus, multiple myeloma, etc.;\n* Women who are pregnant, breastfeeding, or planning pregnancy;\n* Currently participating in other clinical trials investigating drugs for treating proteinuria;\n* Refusal to cooperate with follow-up;\n* Any other reasons deemed by the investigator as unsuitable for participation in this study.",{"count":223,"type":22},40,[225],"PHASE4","This study is a prospective, multicenter, parallel-controlled clinical trial designed to evaluate the therapeutic efficacy of Huaier Granules for proteinuria occurring in lung cancer patients undergoing treatment with either Bevacizumab or Anlotinib.",[29],[229,29,230,231],"Huaier Granules","Bevacizumab","Anlotinib",{"date":233,"type":35},"2026-01-22",{"date":235,"type":22},"2026-01-28",{"date":237,"type":22},"2028-01-28",{"name":239,"class":68},"Fudan University",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":248,"minAge":19,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":256,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":69},"100620264","phase-2-huaier-granule-and-proteinuria-100620264","NCT07355361","Huaier Granule and Proteinuria","Multicenter, Randomized, Parallel-Controlled Clinical Trial on Huaier Granule for Proteinuria Associated With Immunotherapy and Anti-Angiogenic Therapy in Breast Cancer Patients","N093","Inclusion Criteria:\n\n* \\*\\*Inclusion Criteria\\*\\*\n\n  1. Female patients aged 18-75 years.\n  2. Histopathologically confirmed diagnosis of breast cancer.\n  3. Currently receiving or having a prior history of immunotherapy and\u002For anti-angiogenic therapy.\n  4. First-time detection of proteinuria on urinalysis, graded as +, ++, or +++.\n  5. 24-hour urinary protein quantification between 0.15g and 3.5g (exclusive).\n  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n  7. Karnofsky Performance Status (KPS) score ≥70.\n  8. No prior treatment with Huaier Granule within one month before enrollment.\n  9. Life expectancy of at least 6 months.\n  10. Willingness to voluntarily participate in the study and provision of signed informed consent.\n\nExclusion Criteria:\n\n* \\*\\*Exclusion Criteria\\*\\*\n\n  1. Known history of chronic kidney disease (eGFR \\\u003C60 ml\u002Fmin\u002F1.73m²) or diabetic nephropathy.\n  2. Proteinuria attributed to other diseases, including but not limited to primary renal disease, hypertension, urinary tract infection, systemic lupus erythematosus, or multiple myeloma.\n  3. Current use of ACEI\u002FARB medications (unless the dosage has been stable for ≥4 weeks prior to enrollment).\n  4. Known allergy, contraindication, or specific precaution to any component of Huaier Granule.\n  5. Women who are pregnant, breastfeeding, or planning to conceive.\n  6. Concurrent participation in any other clinical trial investigating medications for proteinuria.\n  7. Any other condition that, in the judgment of the investigator, would make the patient unsuitable for participation in this study.","FEMALE","75 Years",{"count":251,"type":22},120,[104],"The goal of this clinical trial is to learn if adding Huaier Granule to standard care can treat proteinuria (excess protein in the urine) in adult female breast cancer patients (aged 18-75) who developed this condition as a side effect of their immunotherapy or anti-angiogenic cancer treatment.\n\nThe main question it aims to answer is:\n\n\\* Does the addition of Huaier Granule to standard care improve the effectiveness of proteinuria treatment after 8 weeks?\n\nResearchers will compare the group receiving standard care plus Huaier Granule to the group receiving standard care alone to see if the combination is more effective at reducing protein levels in the urine.\n\nParticipants will:\n\n* Be randomly assigned to one of the two study groups.\n* Continue their prescribed anti-cancer therapy (immunotherapy or anti-angiogenic therapy).\n* Receive standard medical care for proteinuria from a kidney specialist.\n* If in the experimental group, take Huaier Granule orally, three times a day.\n* Attend clinic visits every 4 weeks for up to 24 weeks for check-ups and tests, including urine and blood tests.",[29,255],"Breast Cancer Patients",[144,257,258,259],"Immunotherapy","Anti-angiogenic therapy","Breast cancer patients","2026-01-13",{"date":262,"type":35},"2026-01-21",{"date":264,"type":22},"2026-01-15",{"date":266,"type":22},"2028-06-15",{"name":239,"class":68},{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":278,"conditions":279,"keywords":282,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100618410","chart-c3gclnp023b12011-100618410","NCT07331259","CHART-C3G\u002FCLNP023B12011","C3 Glomerulopathy Patient Characteristics and Treatment Response to Iptacopan in Routine Care: Analysis of Medical Charts (CHART-C3G)","Inclusion Criteria:\n\n* Clinical diagnosis of C3G (confirmed by biopsy, only if available)\n* Aged ≥18 years at time of index date.\n* At least 6 months of baseline period preceding index date.\n* Users of iptacopan treatment including those who have discontinued iptacopan within the last twelve weeks.\n\nExclusion Criteria:\n\n* Interventional C3G clinical trial participation","100 Years",{"count":277,"type":22},83,"This is a non-interventional chart abstraction cohort study with longitudinal follow up. Patients with C3G treated with iptacopan will be enrolled and characterized (i.e., systematically describe and summarize) regarding their medical history and iptacopan use and evaluated for clinical events, outcomes, and laboratory measurements upon and after iptacopan treatment initiation. Medical charts will be used to obtain secondary pseudonymized patient-level data with reference to 2 time anchors: at index date (date of iptacopan treatment initiation) with baseline covering 12 months prior to index date, and at 12-month follow-up (twelve months after the index date).The observation period includes baseline plus follow-up.\n\nIptacopan will be used as prescribed by the clinician in accordance with the terms of the marketing authorization. This Novartis-sponsored study, mainly executed by a contract research organization (CRO), will use secondary data from EHR obtained through reference centers\u002F centers of excellence in glomerular diseases in Germany.\n\nThe primary objective of this study is to characterize the demographic and clinical profiles of adult patients diagnosed with C3G upon iptacopan treatment initiation.",[280,281,29],"C3 Glomerulopathy","Complement-mediated Kidney Disease",[283,284,285,286,287],"NIS-PDC","Germany","C3G","Iptacopan","estimated Glomerular Filtration Rate","2025-12-29",{"date":290,"type":35},"2026-01-09",{"date":292,"type":22},"2026-01-01",{"date":294,"type":22},"2027-03-01",{"name":296,"class":42},"Novartis Pharmaceuticals",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":305,"sex":17,"minAge":306,"maxAge":19,"enrollmentInfo":307,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":309,"conditions":310,"keywords":328,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":69},"100420250","pediatric-hypertension-and-the-renin-angiotensin-system-phrase-100420250","NCT04752293","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage","PHRASE","INCLUSION CRITERIA: HYPERTENSION COHORT\n\n* 7-18 years of age at time of enrollment\n* Confirmed new diagnosis of primary hypertension: no identifiable secondary cause, referred to hypertension or nephrology clinic\n\n  * Age \\\u003C13 years: BP ≥95th %ile or ≥130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥130\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: HYPERTENSION COHORT\n\n* \\\u003C7 years or \\>18 years of age at time of enrollment\n* BP confirmed as normal or in the elevated BP category based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C95th %ile or \\\u003C130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C130\u002F80 mmHg\n* A confirmed secondary cause of hypertension\n* Confounding medical condition (heart or kidney disease \\[except hypertension-associated heart changes on echocardiogram or albuminuria\\], vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State\n\nINCLUSION CRITERIA: CONTROL COHORT\n\n* 7-18 years of age at time of enrollment\n* Normal BP based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C90th %ile or \\\u003C120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C120\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: CONTROL COHORT\n\n* \\\u003C7 or \\>18 years of age at time of enrollment\n* Elevated BP or hypertension, based on ≥3 prior office BP measurements on separate days:\n\n  * Age \\\u003C13 years: BP ≥90th %ile or ≥120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥120\u002F80 mmHg\n* History of elevated BP or hypertension\n* Current use of BP-lowering medications\n* Confounding medical condition (heart or kidney disease, vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State",true,"7 Years",{"count":308,"type":22},125,"Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at Atrium Health Wake Forest Baptist and Atrium Health Levine Children's Hospital. Healthy control participants will be recruited from local general primary care practices. Collecting blood and urine samples to analyze components of the renin-angiotensin-aldosterone system (Ang-(1-7), ACE2, Ang II, ACE), uric acid, and klotho, and measuring blood pressure, heart structure and function, autonomic function, vascular function, and kidney function at baseline, year 1, and year 2. Objectives are to investigate phenotypic and treatment response variability and to causally infer if Ang-(1-7), ACE2, Ang II, ACE, uric acid, and klotho contribute to target organ injury due to hypertension.",[311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,29,327],"Hypertension","Left Ventricular Hypertrophy","Left Ventricular Dysfunction","Left Atrial Dilatation","Left Ventricular Diastolic Dysfunction","Kidney Diseases","Kidney Injury","Kidney Dysfunction","Sodium Urine High","Blood Pressure Disorders","Uric Acid Retention","Angiotensin Hypertension","Autonomic Dysfunction","Autonomic Imbalance","Pediatric Kidney Disease","Pediatric Obesity","Albuminuria",[329,330,311,331,332,312,327,333,334,335,336,337,338,339,340,341,342,343,344,345,315,317,346,347,326,348,349,350,351],"High Blood Pressure","Elevated Blood Pressure","Pediatric Hypertension","Target Organ Damage","Uric Acid","Klotho","Fibroblast Growth Factor 23","Renin-Angiotensin-Aldosterone System","Renin-Angiotensin System","Angiotensin-(1-7)","Angiotensin II","Angiotensin-Converting Enzyme 2","Angiotensin-Converting Enzyme","Causal Inference","Causal Mediation Analysis","Sensitivity Analysis","Predictive Analysis","Heart Rate Variability","Sodium","Lifecourse","Kidney Function","Ambulatory Blood Pressure Monitoring","Echocardiogram","2025-12-04",{"date":354,"type":35},"2025-12-11",{"date":356,"type":35},"2021-05-19",{"date":358,"type":22},"2026-12",{"name":360,"class":68},"Wake Forest University Health Sciences",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":368,"enrollmentInfo":369,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":370,"conditions":371,"keywords":372,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":69},"100140089","proteinuria-in-pre-and-post-transplant-100140089","NCT01094327","Proteinuria in Pre and Post Transplant","Evaluation of Recipients With and Without Proteinuria, Pre and Post Kidney Transplantation","Inclusion Criteria:\n\n* Kidney transplant recipients\n* Pediatric males and females up to the age of 25 years old.\n\nExclusion Criteria:\n\n* Transplant recipients other than kidney","25 Years",{"count":21,"type":22},"Patients with focal segmental glomerulosclerosis (FSGS) who progress rapidly to end stage renal disease (ESRD) are at highest risk for development of recurrence of proteinuria following kidney transplantation. This study will look at serum specimens pre and post transplant, as well as kidney transplant specimens pre and post reperfusion to identify where the defects has occured that results in recurrence of proteinuria in a given kidney transplant.",[29],[373],"focal segmental glomerulosclerosis","2025-11-20",{"date":376,"type":35},"2025-11-21",{"date":378,"type":35},"2008-02",{"date":380,"type":22},"2026-11-30",{"name":382,"class":68},"University of Miami",{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":69},"100595318","phase-4-nefecon-and-ambrisentan-in-iga-nephropathy-100595318","NCT07030894","Nefecon and Ambrisentan in IgA Nephropathy","A Prospective, Single-Arm Clinical Study of Budesonide in Combination With Ambrisentan for the Treatment of Patients With IgA Nephropathy","BAIN","Inclusion Criteria:\n\n* Diagnosed with IgA nephropathy by pathological biopsy within 4 years;\n* Age between 18 and 70 years old;\n* 0.5g\u002F24h ≤ 24-hour urinary protein;\n* The estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI formula satisfies: eGFR ≥ 30 mL\u002Fmin\u002F1.73 ㎡\n\nExclusion Criteria:\n\n* Exclude special pathological or clinical kidney disease types such as crescentic glomerulonephritis (pathological diagnosis\\>50%), minimal change nephropathy with IgA deposition, etc;\n* Exclude secondary IgA nephropathy, including allergic purpura, ankylosing spondylitis, systemic lupus erythematosus, Sjogren's syndrome, viral hepatitis, cirrhosis, rheumatoid arthritis, and mixed connective tissue disease;\n* Select patients who have experienced any of the following cardiovascular events within the previous 12 weeks: myocardial infarction, unstable angina, ventricular arrhythmia, New York Heart Association class II or above heart failure, stroke, etc;\n* Within 12 weeks prior to the first medication, systemic use (excluding local and nasal inhalation use) of immunosuppressants, including but not limited to glucocorticoids, cyclophosphamide, azathioprine, mycophenolate mofetil, leflunomide, tacrolimus, cyclosporine, rituximab, Tripterygium wilfordii, etc; Have used an endothelin receptor antagonist within 12 weeks prior to the first medication;\n* Active tuberculosis patients and untreated latent tuberculosis patients;\n* Patients with active hepatitis or latent hepatitis B (patients with HBcAb positive and HBV DNA positive); According to the results of the five hepatitis B tests, patients with HBsAg positivity should be excluded; Patients who are HBsAg negative but HBcAb positive, regardless of whether HBsAb is positive or negative, need to be tested for HBV-DNA to determine their condition: if HBV-DNA is positive, the patient needs to be excluded; If HBV-DNA is negative, patients can participate in the trial;\n* History of immunodeficiency diseases or positive HIV test results (enzyme-linked immunosorbent assay and protein immunoblotting);\n* Patients diagnosed with malignant tumors within the past 5 years, except for treated basal cell carcinoma of the skin, effectively resected squamous cell carcinoma of the skin, colon polyps, or cervical cancer in situ;\n* Patients undergoing kidney transplantation;\n* Pregnant women, lactating women, and men or women with fertility plans during the trial period;\n* For individuals allergic to human derived biological products;\n* Patients who have received any clinical trial medication within 4 weeks prior to their first use;\n* Participants deemed unsuitable by researchers.","70 Years",{"count":393,"type":22},129,[225],"Application of Budesonide in Combination with Ambrisentan in the treatment of IgA nephropathy with progression ESKD risk (24-hour urinary protein ≥ 0.5g\u002F24h), observing the degree and safety of reducing urinary protein and delaying eGFR progression, and observing changes in serum Gd-IgA1 levels",[397,28,29],"IgA Nephropathy",[29,397,399,400,401],"Budesonide","Ambrisentan","Single-arm trial","2025-09-09",{"date":404,"type":35},"2025-09-15",{"date":406,"type":35},"2025-09-01",{"date":408,"type":22},"2026-12-31",{"name":410,"class":68},"The First Hospital of Jilin University",{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":69},"100587078","phase-2-beneficial-effect-of-amiloride-on-progression-of-chronic-kidney-disease-100587078","NCT06923709","Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease","A-CKD","Inclusion criteria\n\nParticipants are eligible to be included in the study, only if all the following criteria apply:\n\n1. Participant must be 18 years of age including at the time of signing the informed consent.\n2. A clinical diagnosis of chronic kidney disease and:\n\n   1. eGFR ≥ 25 mL\u002Fmin\u002F1.73m2 and \\\u003C 60mL\u002F min\u002F1.73m2 at screening\n   2. UACR of ≥ 300mg\u002Fg at screening\n3. Participants must be on stable antihypertensive treatment 2 weeks before start of study drug and throughout study duration.\n4. Office blood pressure at screening meeting (visit 1), \\> 110\u002F60mmHg and \\\u003C 150\u002F90mmHg. If BP \\> 150\u002F90mmHg at visit 1, screening phase can be prolonged to 4 weeks#.\n5. Capable of giving signed informed consent.\n6. Women with childbearing potential\\* can only be included if a pregnancy test is negative at the screening visit. Moreover, women should be using contraception during the study.\n\n   * If the office blood pressure varies by approximately ±10 mmHg and is deemed acceptable by the investigator, the participant can be included.\n\n     * Women are considered of childbearing potential following menarche and until becoming post-menopausal (12 consecutive months without a menstrual period) unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy or bilateral oophorectomy (According to the Clinical Trial Facilitation Group, 2014-09-15).\n\nExclusion criteria\n\nParticipants are excluded from the study is any of the following criteria apply:\n\n1. Treatment with amiloride alone or in combination or use of other types of K-sparing diuretics, MR antagonists (Spironolactone, eplerenone, finerenone)\n2. Ongoing cancer treatment\n3. Treatment with immunosuppressive therapy within 6 months prior to screening\n4. History of organ transplantation\n5. Evidence of current infection (CRP\\> 50 and temperature \\> 38◦C)\n6. History of unstable or rapidly progressing renal disease (eGFR decreasing \\> 5ml\u002Fmin\u002F1.73m2 the last 2 months)\n7. Severe hepatic insufficiency classified as Child-Pugh C\n8. Patients on hypertension treatment who is not on stable antihypertensive treatment 2 weeks before start of study drug.\n9. Pregnancy or breastfeeding participants\n10. Congestive heart failure NYHA class IV, unstable or acute congestive heart failure.\n11. Recent cardiovascular events in a patient:\n\n    1. Less than two months post coronary artery revascularization.\n    2. Acute stroke or TIA within two months prior to screening\n    3. Acute coronary syndrome within two months prior to screening\n12. Patients who, in the judgement of the investigator may be at risk for dehydration.\n13. Known hypersensitivity to the study treatment (active substance or excipients)\n14. Known hypersensitivity to resonium\n15. Addison´s disease\n16. Gastric bypass operation\n17. Participation in other interventional trials\n18. Lactose intolerance\n19. Plasma potassium \\>4.9 mmol\u002Fl at screening",{"count":223,"type":22},[104],"This is a randomized, placebo-controlled, double-blinded crossover trial testing the effects of amiloride in patients with chronic kidney disease (CKD) and proteinuria.\n\nIn CKD with proteinuria, there is aberrant filtration of serine proteases and complement precursors into the tubular lumen. The interaction of these factors leads to proinflammatory complement activation, which may promote inflammation, opsonization, and formation of the membrane-attack complex, causing cell injury.\n\nWith the aim of preserving kidney function, reducing cardiovascular morbidity, and delaying renal replacement therapy in CKD, this study tests whether amiloride (10 mg\u002Fday) protects the filtration barrier, lowers albuminuria, and mitigates kidney inflammation through urokinase inhibition, independent of blood pressure effects.\n\nParticipants are randomized to receive amiloride (10 mg\u002Fday) or placebo for one week, with a 2-3-week washout period in between. Blood and urine samples are collected before and after each treatment period. Additionally, ECG, body composition measurements, blood pressure, and body weight are monitored.\n\nThe primary outcome measures are urinary C3a, soluble C5-9 (sTCC\u002FMAC), and kidney injury biomarkers KIM-1 and NGAL. Secondary endpoints include the urinary albumin\u002Fcreatinine ratio, protein\u002Fcreatinine ratio, and blood pressure.",[422,29],"Chronic Kidney Disease(CKD)","2025-04-10",{"date":425,"type":35},"2025-04-11",{"date":427,"type":35},"2024-10-10",{"date":429,"type":22},"2025-11-01",{"name":431,"class":68},"Odense University Hospital",{"id":433,"slug":434,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":23,"phases":442,"briefSummary":443,"conditions":444,"keywords":448,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":69},"100582758","effects-of-exogenous-ketosis-on-proteinuria-and-renal-function-100582758","NCT06867471","Effects of Exogenous Ketosis on Proteinuria and Renal Function","Effects of Exogenous Ketosis on Proteinuria and Renal Function in Patients with Chronic Kidney Disease and Patients with Polycystic Kidney Disease","KETO-CKD","Inclusion Criteria\n\nStudy A (patients with CKD):\n\n* ACR \\> 200 mg\u002Fg \\\u003C3000 mg\u002Fg\n* eGFR \\>30 ml\u002Fmin\u002F1,73m2\n* Treatment with Renin-Angiotension System (RAS) blockers and SGLT-2 inhibitors for a minimum of 4 weeks prior to inclusion\n* Safe contraception if women in childbearing age\n\nStudy B (patients with PKD):\n\n* Prior diagnose with PKD\n* eGFR \\>30 ml\u002Fmin\u002F1,73m2\n* Treatment with Renin-Angiotension System (RAS) blockers for a minimum of 4 weeks prior to inclusion\n* Safe contraception if women in childbearing age\n\nExclusion Criteria (Study A+B)\n\n* Diabetes Mellitus type 1\n* Heart Failure\n* Liver Disease\n* Kidney transplant\n* Malignant diseases (except skin cancer)\n* Recent acute myocardial infarction (AMI), apoplexia\u002Ftransient ischemic attack (TIA) (within 3 months of inclusion)\n* Pregnancy or breast feeding\n* Alcohol or drug abuse\n* Periodic fasting within four weeks of inclusion\n* Routinely intake of ketogenic diet within four weeks of inclusion\n* Treatment with nitrate",{"count":441,"type":22},43,[166],"A randomized, placebo-controlled, double-blinded crossover study will be conducted. Fourteen patients with polycystic kidney disease (PKD) and 29 patients with proteinuric kidney disease will receive ketone bodies (Ketone-IQ) and placebo in a randomized order. Each treatment period is four weeks. There will be a wash-out period of two weeks in between treatment periods. Effect variables will be measured in the last day of each treatment period.",[445,446,29,447],"Renal Insufficiency, Chronic","Polycystic Kidney Diseases","Ketosis",[449,450,451,447,29,452],"Kidney physiology","Glomerular Filtration Rate","Chronic Kidney disease","Natriuresis","2025-03-06",{"date":455,"type":35},"2025-03-10",{"date":457,"type":35},"2024-09-11",{"date":459,"type":22},"2025-12",{"name":461,"class":68},"Gødstrup Hospital",{"id":463,"slug":464,"hasResults":11,"nctId":465,"briefTitle":466,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":305,"sex":17,"minAge":4,"maxAge":19,"enrollmentInfo":469,"targetDuration":18,"studyType":54,"phases":4,"briefSummary":471,"conditions":472,"keywords":477,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":4},"100576988","biomarkers-and-outcome-predictors-of-pediatric-nephrotic-syndrome-a-genetic-transcriptomic-and-secretome-multiomics-study-100576988","NCT06792448","Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study","PRECISE","Inclusion Criteria:\n\n* Clinical diagnosis of idiopathic nephrotic syndrome (INS) with nephrotic range proteinuria (uPr\u002FuCr ratio \\> 2 mg\u002Fmg).\n* Hypoalbuminemia with serum albumin \\\u003C 3.0 g\u002FdL.\n* Presence of edema.\n* No prior treatment for idiopathic nephrotic syndrome.\n* Age between 1 and 18 years at the time of enrollment.\n* igned informed consent by a parent or legal guardian.\n\nExclusion Criteria:\n\n* Diagnosis of congenital or infantile nephrotic syndrome (age \\\u003C 1 year).\n* Diagnosis of secondary nephrotic syndrome.\n* Presence of glomerulonephritis, autoimmune diseases, or vasculitis.\n* Lack of signed informed consent by a parent or legal guardian.\n* Previous treatment with prednisone or prednisolone for nephrotic syndrome.",{"count":470,"type":22},350,"Idiopathic Nephrotic Syndrome is a rare disease of the kidneys, which typically affects children. For most affected children there is the need of a prolonged treatment with drugs reducing the activity of the immune system, also resulting in many side effects. Those patients, who do not respond to treatment, are at risk of kidney damage and of dialysis or kidney transplantation. It is currently impossible to predict the response to treatment, leading to unnecessary therapies with side effects as well as unclear prognosis in the affected children. The response of the idiopathic nephrotic syndrome to medications acting on the immune system explains its important role in the occurrence of the disease.\n\nWith this study we aim to obtain predictors of the response to treatment right at the beginning of the disease, to adapt the therapy avoiding needless side effects. This will be done evaluating the blood and urine of affected children using state of the art molecular characterisation. We will evaluate the genetic predisposition, the cell trait changes and the presence of molecules in blood and urine that may affect the interaction between the immune system and the kidneys. We expect that the findings will improve treatment of children with idiopathic nephrotic syndrome and reduce the number of children suffering from unnecessary drugs related side effects.",[473,474,475,170,29,476,316,28],"Nephrotic Syndrome Steroid-Dependent","Nephrotic Syndrome Steroid-Resistant","Nephrotic Syndrome in Children","Hypoalbuminemia",[478,479,480,481,482,483,484,485,486,487,488,489,490,491,492],"Pediatric nephrotic syndrome","Idiopathic nephrotic syndrome","Steroid-resistant nephrotic syndrome","Steroid-sensitive nephrotic syndrome","Biomarkers discovery","Genetic risk factors","Epigenetic analysis","Adaptive immune system profiling","Liquid biopsy","Serum and urine proteomics","Multiomics approach","Personalized treatment","Disease progression prediction","Molecular characterization","Pediatric kidney disease","2025-01-28",{"date":495,"type":35},"2025-01-30",{"date":497,"type":22},"2025-02-15",{"date":499,"type":22},"2028-06-01",{"name":501,"class":68},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":249,"enrollmentInfo":509,"targetDuration":4,"studyType":23,"phases":511,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":69},"100553888","comparison-of-the-role-of-losartan-alone-vs-hydrochlorothiazide-plus-losartan-100553888","NCT06491940","Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan","Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan on Proteinuria in Diabetic Nephropathy Patients","Inclusion Criteria:\n\n* Patients of both genders with ≥18 years of age.\n* Presence of proteinuria\u002Falbuminuria at time of screening.\n* Creatinine clearance of 30 mL\u002Fmin or higher.\n\nExclusion Criteria:\n\n* A systolic blood pressure of 180 mm Hg or higher, a diastolic blood pressure of 110 mm Hg or higher.\n* Presence of a second primary renal disease in addition to diabetic nephropathy.\n* Patients with type 1 diabetes.\n* A history of a cardiovascular or cerebrovascular event within 3 months before inclusion.\n* Serum potassium of 6.0 mmol\u002FL or higher.\n* Transplantation or immunosuppressive treatment.\n* Contraindication for the use of losartan or hydrochlorothiazide.\n* Pregnancy or lactation.",{"count":510,"type":22},234,[166],"Losartan, an angiotensin II receptor blocker, has already been established as a treatment for diabetic nephropathy due to its ability to reduce blood pressure and mitigate the progression of kidney damage. However, the addition of a diuretic like hydrochlorothiazide may offer synergistic benefits in reducing proteinuria by addressing both the underlying renal pathology and potential volume overload in these patients. The current study aims at determining and comparing the role of losartan alone vs hydrochlorothiazide plus losartan in reducing proteinuria in diabetic nephropathy patients.",[29],"2024-07-01",{"date":516,"type":35},"2024-07-09",{"date":518,"type":22},"2024-08-01",{"date":520,"type":22},"2025-07-31",{"name":522,"class":68},"RESnTEC, Institute of Research",{"id":524,"slug":525,"hasResults":11,"nctId":526,"briefTitle":527,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":249,"enrollmentInfo":529,"targetDuration":51,"studyType":54,"phases":4,"briefSummary":530,"conditions":531,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":69},"100528574","arrest-nephrosis---austrian-resistant-nephrotic-syndrome-treatment-response-registry-and-biobank-100528574","NCT06162546","ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank","Inclusion Criteria:\n\n* Resistant to standard Immunosuppressive agents (if clinically indicated, e.g. primary\u002Fnon-genetic forms)\n* Persistent urinary protein-to-creatinine (UP\u002FC) ratio \\>1.0 g\u002Fg\n* eGFR \\> 30 ml\u002Fmin per 1.73 m2\n* biopsy or a disease-causing genetic mutation associated with nephrotic syndrome\n\nExclusion Criteria:\n\n* Inability or unwillingness to comply with repeated assessments\n* Objections against participation at discretion of the investigator\n* Secondary\n* Patients with steroid-dependence\u002Ffrequently relapsing disease (but achievement of complete remission)",{"count":21,"type":22},"Nephrotic syndrome is the clinical phenotype of a heterogeneous group of glomerular diseases that may present with varying degrees of urinary protein loss (proteinuria), dysproteinemia in the blood, fluid retention and impaired renal function.\n\nThe AustRian RESistanT NEPHROtic Syndrome Treatment Response RegIStry and Biobank (ARREST-NEPHROSIS) sets out to achieve the following goals, as typical categories of rare disease registries\n\n1. Obtaining real world data on practice patterns and outcomes\n2. Networking between affected patients, families, and clinicians.\n3. Establish a patient base for facilitated recruitment in studies of drugs, medical devices, and products\n4. Development of a Biobank to enable research of potential biomarkers and therapy or disease courses",[532,29,107,474],"Focal Segmental Glomerulosclerosis","2023-11-30",{"date":535,"type":35},"2023-12-08",{"date":537,"type":35},"2023-01-01",{"date":539,"type":22},"2033-12-31",{"name":541,"class":68},"Christoph Aufricht"]